Global pharmaceutical company Mallinckrodt Plc (NYSE: MNK) has entered an agreement to buy Rockville’s Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) for $1.2 billion, including debt. U.K.-based Mallinckrodt, which has its U.S. headquarters in the St. Louis area, is making the purchase to gain access to Sucampo’s flagship drug, Amitiza, which treats constipation. The deal is expected to close in the first quarter of 2018. “With the addition of its significant resources and expertise, we believe Mallinckrodt is…
from https://www.bizjournals.com/baltimore/news/2017/12/27/sucampo-pharmaceuticals-to-be-acquired-in-1-2b.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/168997190947
No comments:
Post a Comment